शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEPHAARMASIA LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 13 Aug, 2026 · 17:59 IST

Phaarmasia Q1FY27 PAT turns positive at Rs 33.90 lakh, revenue up 20%

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-8.9%Reaction day
₹84.50
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-8.9% vs market
Pharmaceuticals peers, median of 166sector-0.4%-8.5% vs sector

On the reaction day the stock moved 8.9 pts less than Nifty Microcap 250 and 8.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-8.9+0.1-8.9-0.4-8.5
Next day
-9.3+0.2-9.5-0.3-9.0
2d
-18.4+0.6-19.0-0.5-17.8
3d
-9.5-0.0-9.5-1.3-8.2
4d
-8.4+0.5-8.9-0.8-7.6
5d
-10.1+0.8-10.8-0.4-9.7
1w
-10.1+0.6-10.6-0.9-9.2
15d
-2.7+1.3-3.9+0.0-2.7
1m
+0.6-1.4+1.9-0.1+0.7
2m
-4.3-0.6-3.7-2.6-1.7
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Phaarmasia Ltd posted Q1FY27 revenue of Rs 828.33 lakh, up about 20.5% YoY from Rs 687.36 lakh. Net profit swung to Rs 33.90 lakh versus a loss of Rs 70.30 lakh in Q1FY26. Profit before tax was Rs 30.44 lakh against a loss of Rs 53.61 lakh. Results include an exceptional gain of Rs 31.31 lakh from sale of land and building. Auditor Sathuluri and Co issued an unqualified limited review report.

Likely market impact

Revenue and PAT show a strong YoY turnaround aided by a one-time land sale gain; underlying operations also look healthier.